Treatment of Alloxan-Induced Diabetic Rats with Metformin or Glitazones is Associated with Amelioration of Hyperglycaemia and Neuroprotection

Oluwole Akinola* , Michael Gabriel, Abdul-Azeez Suleiman and Felix Olorunsogbon

Department of Anatomy, Faculty of Basic Medical Sciences, College of Health Sciences, University of Ilorin, P.M.B. 1515, Ilorin, Nigeria

Abstract: Neurobehavioural and cognitive impairments are reportedly associated with both types of diabetes mellitus; and the structural and molecular aberrations in support of these are emerging. In the present study, we report the effects of induced diabetes and its treatment with or without oral hypoglycaemic drugs on the morphology and oxidative stress status of the prefrontal cortex. Hyperglycaemia was induced in fasted Wistar rats with alloxan (150 mg/kg body weight). Hyperglycaemic rats were treated with or without oral hypoglycaemic drugs (metformin, 150 mg/kg/d; pioglitazone, 3 mg/kg/d; and rosiglitazone, 10 mg/kg/d). At 28 days of treatment, prefrontal morphology was studied by the cresyl fast violet (CFV) and luxol fast blue (LFB) techniques; and malondialdehyde (MDA) and superoxide dismutase (SOD) were assayed in prefrontal homogenate. Blood glucose was estimated by the glucose oxidase method. Prefrontal cortex neurons showed weak affinity for CFV and LFB in the untreated diabetic rats; as opposed to the relatively strong affinity for these stains in the non-diabetic control rats and diabetic rats on oral hypoglycaemic interventions. In the latter, blood glucose was not significantly different (P>0.05) from the control at 28 days of treatment. Moreover, prefrontal MDA and SOD were not significantly different between all the groups (P>0.05). These findings suggest that morphologic aberrations are provoked by untreated diabetes mellitus, even in the absence of oxidative stress; and that oral hypoglycaemic interventions are neuroprotective in alloxan-induced diabetic rats.

Keywords: Metformin, pioglitazone, rosiglitazone, neuron, neuroprotection, diabetes.

INTRODUCTION

One of the several complications of diabetes mellitus is neuropathy, which could involve both the central and peripheral nerve tissues. Cerebral involvement in diabetic lesions may manifest as impairment of learning, cognition and memory in human and animals [1]. Diabetes is also a risk factor for vascular dementia and Alzheimer’s disease [2].

Recent studies are unravelling the structural and molecular changes characteristic of the brain in chronic diabetes patients and experimental animals. Such changes include smaller volume of the grey matter and relatively high white matter lesions [3]; lower brain-to-intracranial volume ratios [4]; and grey matter atrophy [5] in human subjects. In animal studies of diabetic neuropathy, significant reduction in the density of the dendritic spines of prefrontal pyramidal neurons [6]; neuronal DNA and protein loss in association with brain atrophy [7]; and prefrontal Nissl body deficits [8], have been reported.

However, it has been shown that with optimal glycaemic control, diabetic brain lesions could be prevented and/or ameliorated. In a recent study by Serbedzija et al., [7], treatment of streptozotocin-induced (STZ-induced) diabetic rats with a combination of insulin and insulin-like growth factor I (IGF-I) protected brain tissues from diabetic lesions. Previously, we have also shown that treatment of STZ-induced diabetic rats with a botanical intervention from neem and bitter leaf was protective against diabetes brain injury [8].

In the present work, we studied the effect of induced diabetes on the morphology of the prefrontal neurons; as well as on some tissue markers of oxidative stress (malondialdehyde and superoxide dismutase). We also tested the hypothesis that treatment of rats with hypoglycaemic drugs is protective against diabetes-induced brain lesions.

MATERIALS AND METHODS

Animals

Male Wistar rats (average weight: 140 g) were bred and maintained on rodent chow from Bendel Feed (Ewu, Nigeria). All animals were exposed to an environment of 12 hour light:12 hour dark period, at a room temperature between 23 °C and 25 °C.

Induction of Hyperglycaemia

A cohort of male Wistar rats was fasted overnight for at least 8 hours. Hyperglycaemia was induced in each fasted rat by administering alloxan monohydrate (150 mg/ Kg body weight; intraperitoneal) in normal saline. The control cohort was administered normal saline intraperitoneally. At 7 days post-induction of hyperglycaemia, blood glucose was assayed by the glucose oxidase method, using a glucometer.
Only those rats with established hyperglycaemia (blood glucose >300 mg/dl) were included for subsequent treatment.

**Treatment of Hyperglycaemic Rats with Oral Hypoglycaemic Drugs**

Three oral hypoglycaemic drugs (metformin, rosiglitazone and pioglitazone) were used in the present study. Each drug was administered orally to a cohort of hyperglycaemic rats (n=8) at 7:00 – 9:00 each day for 28 days. Metformin (Merck, Germany) was administered at 150 mg/kg body weight/day [9]; rosiglitazone (GlaxoSmithKline, USA) at 3 mg/kg body weight/day [10]; and pioglitazone (Sun, India) at 10 mg/kg body weight/day [11]. Untreated diabetic group received only the vehicle (distilled water).

**Estimation of Blood Glucose**

In the control, non-treated diabetic, and oral hypoglycaemic-treated rats, blood glucose was assayed weekly by the glucose oxidase method.

**Termination of Treatment**

At 28 days of treatment with oral hypoglycaemic drugs, all rats were anaesthetized with ether (Sigma, MO), 24 hours after the last dose of the drugs. Each rat was then decapitated and the brain removed with the brain forceps. For each rat, the prefrontal region (part of the cerebral hemisphere just caudal to the olfactory bulb) was either fixed in formol-calcium or homogenized in phosphate buffered solution (pH 7.4, 0.1 M).

**Bioassays and Histological Processing**

The homogenate from each rat was spun at 500 xg for 10 minutes, in a centrifuge. The supernatant were assayed for total protein and markers of oxidative stress. Protein was assayed by the Biuret method [12]. Tissue malondialdehyde (MDA) and superoxide dismutase (SOD) were assayed by the method of Ohkawa et al., [13] and Misra and Fridovich [14], respectively.

![Fig. (1). Photomicrographs of the prefrontal cortex of the control, non-treated diabetic and oral hypoglycaemic-treated rat brain. Chromatolysis is observable in the non-treated diabetic group (thin arrow), in contrast to the well-stained Nissl substance and nuclei of the neurons in the control and oral hypoglycaemic-treated groups. Cresyl fast violet (Magnification, x400).](image-url)
Moreover, formol-calcium-fixed prefrontal lobes were dehydrated and embedded in paraffin wax. Eight micrometer-thick sections were cut on a rotary microtome; and sections were either stained by the cresyl fast violet (CFV) or luxol fast blue (LFB) technique, as described by Bancroft and Stephens [15]. Images were captured with an MW1-HD2 digital microscope.

Statistical Analysis

Data collected on blood glucose and markers of oxidative stress were analysed and presented as mean ± standard error of the mean (mean ± SEM). Means were compared by the analysis of variance, followed by the Bonferroni post-hoc test. P<0.05 was accepted as significant.

RESULTS

Histologic Findings

In the non-treated diabetic rats, prefrontal neurons showed poorly-stained nuclei and chromatolysis (poorly-stained Nissl bodies), as demonstrated by the CFV technique (Fig. 1). However, in the non-diabetic control and hypoglycaemic drug-treated diabetic rats, prefrontal cortex neurons showed well-stained nuclei and Nissl bodies.

Similarly, LFB technique showed poorly myelinated axons in the prefrontal cortex of non-treated diabetic rats (Fig. 2). Axonal integrity was however preserved in the non-diabetic control and hypoglycaemic drug-treated diabetic rats (Fig. 2).

Blood Glucose Levels in the Control and Treatment Groups

The blood glucose responses to oral hypoglycaemic drugs in alloxan-induced diabetic rats are shown in Table 1. At 28 day of treatment, no statistically significant elevation in blood glucose levels occurred in all the groups compared to the control rats (P>0.05), except in the non-treated diabetic rats, where significant elevations in blood glucose occurred (P<0.05).

![Fig. (2). Photomicrographs of the prefrontal cortex of the control, non-treated diabetic and oral hypoglycaemic-treated rat brain. Loss of myelin sheath is observable in the non-treated diabetic group (thick arrow), in contrast to the intact myelin sheath of the control and hypoglycaemic drug-treated groups (thin arrow). Luxol fast blue (Magnification, x400).](image-url)
Neuroprotective Effect of Metformin and Glitazones in Diabetic Rats

**The Open Diabetes Journal, 2012, Volume 5**

Control rats (P>0.05), as shown in Table groups were not significantly different from the non-diabetic groups (P>0.05). Moreover, SOD activity in all the treatment levels were not significantly different between the non-diabetic control and the treatment groups (Table). Significantly different (P>0.05) between the non-diabetic control and the treatment groups (Table).

**DISCUSSION**

The chronological progression of diabetes mellitus is associated with varying degrees of cognitive deficits in human [16] and animals [17]. The structural changes and mechanisms underlying such diabetes-related neurocognitive impairment are also evolving.

Hyperglycaemia and hypoglycaemia are both risk factors for neurostructural and cognitive impairment of diabetes mellitus. Previous morphologic studies of the brain in diabetic human and animals showed structural impairment of both the white and grey matter. In the recent study of Novak et al., [5] in human subjects, the diabetic brain showed atrophic changes in the grey matter of the frontal, temporal and parietal lobes. This agrees with the findings of Manschot et al., [18], which showed brain atrophy in diabetic subjects using magnetic resonance imaging (MRI) technique.

In the present work, we studied brain (prefrontal cortex) morphology in alloxan-induced diabetic rats with and without treatment with oral hypoglycaemic drugs. Histologic study of the brain of the non-treated diabetic rats showed structural impairment characterised by loss of axonal myelin sheath and poor Nissl staining outcome. The latter suggests loss of Nissl substance and nuclear DNA in the somata of the diabetic brain. Thus, the present morphologic findings from animal studies are empirical evidence of the structural changes of the brain in diabetic conditions.

Table 1. Effect of Oral Hypoglycaemic Drugs on Blood Glucose Levels of Alloxan-Induced Diabetic Rats (mg/dl)

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Week 0</th>
<th>Week 1</th>
<th>Week 2</th>
<th>Week 3</th>
<th>Week 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>8</td>
<td>110±5</td>
<td>105±3</td>
<td>130±6</td>
<td>123±4</td>
<td>125±2</td>
</tr>
<tr>
<td>Non-treated Diabetic</td>
<td>8</td>
<td>480±20a</td>
<td>450±23a</td>
<td>460±19a</td>
<td>370±15a</td>
<td>410±26a</td>
</tr>
<tr>
<td>Diabetic + metformin</td>
<td>8</td>
<td>380±16a</td>
<td>400±20a</td>
<td>160±8b</td>
<td>155±9b</td>
<td>150±10b</td>
</tr>
<tr>
<td>Diabetic + pioglitazone</td>
<td>8</td>
<td>400±16a</td>
<td>390±18a</td>
<td>400±20a</td>
<td>140±9b</td>
<td>180±4</td>
</tr>
<tr>
<td>Diabetic + rosiglitazone</td>
<td>8</td>
<td>410±17a</td>
<td>480±19a</td>
<td>140±11b</td>
<td>95±9b</td>
<td>135±6b</td>
</tr>
</tbody>
</table>

Data are mean ± SEM (mg/dl); a = P < 0.05 compared with control; b = P < 0.05 compared with non-treated diabetic.

**Prefrontal Malondialdehyde and Superoxide Dismutase**

Prefrontal MDA levels and SOD activities were not significantly different (P>0.05) between the non-diabetic control and the treatment groups (Table 2). Similarly, MDA levels were not significantly different between the non-treated diabetic rats and the hypoglycaemic drug-treated groups (P>0.05). Moreover, SOD activity in all the treatment groups were not significantly different from the non-diabetic control rats (P>0.05), as shown in Table 2. However, SOD activity in the pioglitazone-treated diabetic group was significantly higher than the value in the non-treated diabetic rats (P<0.01) (Table 2).

**Table 2. Effect of Oral Hypoglycaemic Drugs on the Prefrontal SOD and MDA of Alloxan-Induced Diabetic Rats**

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>SOD (U/mg Protein)</th>
<th>MDA (nmol/mg Protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>8</td>
<td>365.4±24.0</td>
<td>1.11±0.22</td>
</tr>
<tr>
<td>Non-treated</td>
<td>8</td>
<td>389.0±43.1</td>
<td>0.84±0.15</td>
</tr>
<tr>
<td>Diabetic</td>
<td>8</td>
<td>332.9±49.3</td>
<td>0.69±0.10</td>
</tr>
<tr>
<td>Diabetic</td>
<td>8</td>
<td>459.2±43.8*</td>
<td>0.84±0.16</td>
</tr>
<tr>
<td>Diabetic</td>
<td>8</td>
<td>376.6±6.8</td>
<td>0.73±0.11</td>
</tr>
</tbody>
</table>

Data are mean ± SEM; *P < 0.01 compared with non-treated diabetic control.
treated groups. This suggests that optimum glycaemic control protects against neural lesions in diabetic rats. A recent study by Serbedzija et al. [7] also showed neuroprotection by insulin and insulin-like growth factor I (IGF-I) against brain atrophy in streptozotocin-induced diabetic rats.

Moreover, in human studies, optimum glycaemic control improved cognitive and social functions in diabetic subjects [19]. These latter findings in diabetic subjects, and our histologic observations in the present animal study, underscore the importance of optimum glycaemic control to brain morphology and functions in the diabetic state.

Furthermore, results from the present oxidative stress studies in diabetic rats suggest that the structural lesions observed in the non-treated diabetic rats were not the consequence of oxidative damage. MDA and SOD levels were not significantly different from the control in all the treatment groups (Table 2). Thus, it is unlikely from the present data that oxidative stress contributed to the neural lesions seen in the non-treated diabetic rats. That is, the data from the present animal study suggests that neural lesions could occur in the diabetic state in the absence of oxidative stress.

In conclusion, data from the present study shows that neural lesions are induced by untreated diabetic mellitus, even in the absence of oxidative stress; and that metformin and glitazones are neuroprotective in alloxan-induced diabetic rats.

ACKNOWLEDGEMENTS

None declared.

CONFLICT OF INTEREST

Authors declare no conflict of interest.

REFERENCES